Targeting of viral interleukin-10 with an antibody fragment specific to damaged arthritic cartilage improves its therapeutic potency

Arthritis Research and Therapy

Volumn 16, Issue 4, 2014, Pages

  Hughes, Chris ^a   Sette, Angelica ^a   Seed, Michael ^b   D'Acquisto, Fulvio ^a   Manzo, Antonio ^c   Vincent, Tonia L ^d   Lim, Ngee H ^a   Nissim, Ahuva ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF EAST LONDON   (United Kingdom)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; HYBRID PROTEIN; INTERLEUKIN 10; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; REACTIVE OXYGEN SPECIES COLLAGEN TYPE II SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY MATRIX METALLOPROTEINASE INTERLEUKIN 10 FUSION PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STROMELYSIN; UNCLASSIFIED DRUG; COLLAGEN TYPE 2; IMMUNOGLOBULIN VARIABLE REGION; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CARTILAGE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEK293 CELL LINE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOARTHRITIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING; ANIMAL; ANTIBODY SPECIFICITY; ARTICULAR CARTILAGE; C57BL MOUSE; DRUG DELIVERY SYSTEM; EXPERIMENTAL ARTHRITIS; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

ANIMALS; ANTIBODY SPECIFICITY; ARTHRITIS, EXPERIMENTAL; BLOTTING, WESTERN; CARTILAGE, ARTICULAR; COLLAGEN TYPE II; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTHERAPY; INTERLEUKIN-10; MICE; MICE, INBRED C57BL; REACTIVE OXYGEN SPECIES; RECOMBINANT FUSION PROTEINS;

EID: 84904273376     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4613     Document Type: Article

References (32)

1. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7:429-442.
2. Kunz M, Ibrahim SM. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm 2009, 2009:979258. 2768824, 19884985.
3. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 2001, 19:163-196. 10.1146/annurev.immunol.19.1.163, 11244034.
4. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008, 223:7-19. 10.1111/j.1600-065X.2008.00626.x, 18613827.
5. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001, 76:653-656. 10.1016/S0025-6196(11)62418-X, 11393506.
6. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285. 10.1001/jama.295.19.2275, 16705109.
7. Mewar D, Wilson AG. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 2011, 162:785-791. 3042190, 21039421.
8. Winyard PG, Blake DR. Antioxidants, redox-regulated transcription factors, and inflammation. Adv Pharmacol 1997, 38:403-421.
9. Hughes C, Faurholm B, Dell'Accio F, Manzo A, Seed M, Eltawil N, Marrelli A, Gould D, Subang C, Al-Kashi A, De Bari C, Winyard P, Chernajovsky Y, Nissim A. Human single-chain variable fragment that specifically targets arthritic cartilage. Arthritis Rheum 2010, 62:1007-1016. 10.1002/art.27346, 2905615, 20131274.
10. Gu Y, Yang J, Ouyang X, Liu W, Li H, Yang J, Bromberg J, Chen SH, Mayer L, Unkeless JC, Xiong H. Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. Eur J Immunol 2008, 38:1807-1813. 10.1002/eji.200838331, 2733944, 18506885.
11. Boissier MC, Bessis N. Therapeutic gene transfer for rheumatoid arthritis. Reumatismo 2004, 56:51-61.
12. Joosten LA, Lubberts E, Durez P, Helsen MM, Jacobs MJ, Goldman M, van den Berg WB. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997, 40:249-260. 10.1002/art.1780400209, 9041936.
13. Sin SH, Dittmer DP. Cytokine homologs of human gamma herpes viruses. J Interferon Cytokine Res 2012, 32:53-59. 10.1089/jir.2011.0083, 3275093, 22142220.
14. Keravala A, Lechman ER, Nash J, Mi Z, Robbins PD. Human, viral or mutant human IL-10 expressed after local adenovirus-mediated gene transfer are equally effective in ameliorating disease pathology in a rabbit knee model of antigen-induced arthritis. Arthritis Res Ther 2006, 8:R91. 10.1186/ar1960, 1779418, 16704745.
15. Whalen JD, Lechman EL, Carlos CA, Weiss K, Kovesdi I, Glorioso JC, Robbins PD, Evans CH. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 1999, 162:3625-3632.
16. van Roon J, Wijngaarden S, Lafeber FP, Damen C, van de Winkel J, Bijlsma JW. Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fc gamma receptor expression on monocytes and responsiveness to immune complex stimulation. J Rheumatol 2003, 30:648-651.
17. Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, Trachsel E. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 2009, 11:R142. 10.1186/ar2814, 2787264, 19781067.
18. Trachsel E, Bootz F, Silacci M, Kaspar M, Kosmehl H, Neri D. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther 2007, 9:R9. 10.1186/ar2115, 1860067, 17261171.
19. Lim NH, Meinjohanns E, Bou-Gharios G, Gompels LL, Nuti E, Rossello A, Devel L, Dive V, Meldal M, Nagase H. In vivo imaging of matrix metalloproteinase 12 and matrix metalloproteinase 13 activities in the mouse model of collagen-induced arthritis. Arthritis Rheum 2014, 66:589-598.
20. Wengner AM, Hopken UE, Petrow PK, Hartmann S, Schurigt U, Brauer R, Lipp M. CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis. Arthritis Rheum 2007, 56:3271-3283. 10.1002/art.22939, 17907173.
21. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthr Cart 2007, 15:1061-1069.
22. Rosenberg L. Chemical basis for the histological use of safranin O in the study of articular cartilage. J Bone Joint Surg Am 1971, 53:69-82.
23. Lim NH, Meinjohanns E, Medal M, Bou-Gharios G, Nagase H. In vivo imaging of MMP-13 activity in the murine destabilised medial meniscus surgical model of osteoarthritis. Osteoarth Cart 2014, 22:862-868.
24. Horton SC, Emery P. Biological therapy for rheumatoid arthritis: where are we now?. Br J Hosp Med (Lond) 2012, 73:12-18. 10.12968/hmed.2012.73.1.12, 22241404.
25. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975. 10.1136/ard.2009.126532, 2935329, 20444750.
26. van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, Kivitz AJ, Alvaro J, Nuki G, Furst DE, Herrero-Beaumont G, McInnes IB, Musikic P, Tak PP. A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Ann Rheum Dis 2005, 64:64-69. 10.1136/ard.2003.020347, 1755211, 15242865.
27. van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater-Zyberk C, Vervoordeldonk MJ, Tak PP. Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2004, 6:R239-R249. 10.1186/ar1165, 416442, 15142270.
28. Jones BC, Logsdon NJ, Josephson K, Cook J, Barry PA, Walter MR. Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R1. Proc Natl Acad Sci U S A 2002, 99:9404-9409. 10.1073/pnas.152147499, 123153, 12093920.
29. Liu Y, de Waal MR, Briere F, Parham C, Bridon JM, Banchereau J, Moore KW, Xu J. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J Immunol 1997, 158:604-613.
30. Yoon SI, Jones BC, Logsdon NJ, Walter MR. Same structure, different function crystal structure of the Epstein-Barr virus IL-10 bound to the soluble IL-10R1 chain. Structure 2005, 13:551-564. 10.1016/j.str.2005.01.016, 15837194.
31. Ding Y, Qin L, Kotenko SV, Pestka S, Bromberg JS. A single amino acid determines the immunostimulatory activity of interleukin 10. J Exp Med 2000, 191:213-224. 10.1084/jem.191.2.213, 2195749, 10637267.
32. Adams G, Vessillier S, Dreja H, Chernajovsky Y. Targeting cytokines to inflammation sites. Nat Biotechnol 2003, 21:1314-1320. 10.1038/nbt888, 14528315.